Pateclizumab

Pateclizumab is a monoclonal antibody that was designed for the treatment of rheumatoid arthritis. It was developed by Genentech, a biotechnology company based in the United States. Pateclizumab targets the interleukin 6 (IL-6) pathway, which plays a crucial role in the inflammatory response that characterizes rheumatoid arthritis.

Mechanism of Action

Pateclizumab works by binding to the interleukin 6 receptor (IL-6R), thereby inhibiting the interaction between IL-6 and its receptor. This prevents the activation of the IL-6 pathway, which is known to contribute to the inflammation and joint damage seen in rheumatoid arthritis.

Clinical Trials

Pateclizumab has undergone Phase II clinical trials for the treatment of rheumatoid arthritis. The results of these trials showed that pateclizumab was well-tolerated and led to improvements in disease activity scores in patients with rheumatoid arthritis.

See Also

• Monoclonal antibodies
• Rheumatoid arthritis
• Interleukin 6
• Genentech